Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | Guopan Yu, Weiguo Zhang, Charlie Ly, Hongying Zhang, William Rice and Michael Andreeff |
Title | CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status |
Journal | Blood |
Vol | |
Issue | |
Date | |
URL | http://www.bloodjournal.org/content/130/Suppl_1/4629?sso-checked=true |
Abstract Text | Blood 2017 130:4629 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CG-806 | CG'806|CG-026806|CG806|Luxeptinib | BTK inhibitor 34 FLT3 Inhibitor 62 | CG-806 is a small molecule multi-kinase inhibitor that inhibits both wild-type and mutant Flt3 and Btk, resulting in growth inhibition in tumor cells (Blood 2017 130:4629). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 wild-type | acute myeloid leukemia | predicted - sensitive | CG-806 | Preclinical - Cell culture | Actionable | In a preclinical study, CG-806 inhibited Btk and aurora kinase activation, induced G2/M arrest and autophagy in acute myeloid leukemia cells harboring wild-type FLT3 in culture (Blood 2017 130:4629). | detail... |